search
Back to results

Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy

Primary Purpose

Colorectal Cancer, Colorectal Adenoma, Colorectal Neoplasms

Status
Recruiting
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
AI-assisted colonoscopy
Sponsored by
Ismail Gögenur
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Colorectal Cancer focused on measuring Artificial intelligence-assisted colonoscopy, Computer-aided polyp characterization, Colorectal adenoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Referred for screening colonoscopy due to a positive faecal immunochemical test (FIT) or for Diagnostic colonoscopy due to symptoms/signs or Post-polypectomy surveillance colonoscopy (only patients who had all detected polyps removed in the previous colonoscopy) Exclusion Criteria: Referral for removal of previous detected polyps Emergency colonoscopy Control colonoscopy due to inflammatory bowel disease (IBD)

Sites / Locations

  • Holbæk HospitalRecruiting
  • Zealand University HospitalRecruiting
  • Nykøbing Falster County HospitalRecruiting
  • Næstved HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

AI-assisted colonoscopy

Arm Description

The patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).

Outcomes

Primary Outcome Measures

True positive findings: Adenomas (histopathologically verified) characterized as adenomas by the AI system
Data from the AI system will be compared with the histopathological data for each removed polyp
True negative findings: Non-adenomas (histopathologically verified) characterized as non-adenomas by the AI system
Data from the AI system will be compared with the histopathological data for each removed polyp
False positive findings: Non-adenomas (histopathologically verified) characterized as adenomas by the AI system
Data from the AI system will be compared with the histopathological data for each removed polyp
False negative findings: Adenomas (histopathologically verified) characterized as non-adenomas by the AI system
Data from the AI system will be compared with the histopathological data for each removed polyp

Secondary Outcome Measures

Full Information

First Posted
February 3, 2023
Last Updated
February 21, 2023
Sponsor
Ismail Gögenur
Collaborators
Nykøbing Falster County Hospital, Naestved Hospital, Holbaek Sygehus, Slagelse Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05754229
Brief Title
Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy
Official Title
Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy - A Prospective Quality Assurance Study
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 1, 2022 (Actual)
Primary Completion Date
March 3, 2023 (Anticipated)
Study Completion Date
September 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Ismail Gögenur
Collaborators
Nykøbing Falster County Hospital, Naestved Hospital, Holbaek Sygehus, Slagelse Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The goal of this substudy is to investigate the accuracy of a computer-aided polyp characterization (CADx) system. The main question[s] it aims to answer are: • How high is the specificity of the AI system when characterizing colorectal polyps Participants will receive a standard colonoscopy, assisted by the artificial intelligence (AI) assisted system GI Genius. Researchers will compare the AI system´s characterization with the histopathology to see how accurate the system is.
Detailed Description
Colorectal cancer (CRC) is the third most common cancer, and the second most common cause of cancer-related death worldwide. CRC screening is used for detection and removal of precancerous lesions before they develop into cancer. Colonoscopy is regarded being superior to other screening tests, and is therefore used as the golden standard. Screening colonoscopy is associated with a reduced risk of CRC-related death. Since it is not possible for an endoscopist to determine the histopathology of the polyp with certainty during a colonoscopy, detected pre-malignant lesions should be removed and sent for histological examination. Multiple studies have shown that there is a strong association between findings at the baseline screening colonoscopy and rate of serious lesions at the follow up colonoscopy. Risk factors for adenoma, advanced adenoma and cancer at follow-up colonoscopy are multiplicity, size, villousness, and high degree dysplasia of the adenomas at the baseline screening colonoscopy. Within the last few years there have been published several randomized controlled trials (RCT) investigating the efficacy of real time computer-aided detection. Studies have shown that AI contributes to a significantly higher adenoma detection rate (ADR), compared colonoscopies without assistance of an AI system.There have been concerns about prolonged colonoscopy time, and increased workload if implementing the AI-system, since the increased detection of small polyps may lead to unnecessary polypectomy. With the development of computer-aided polyp characterization (CADx) systems, it is possible to use AI for decision support and not only for detection. There is no evidence yet that the CADx system increases the sensitivity for small neoplastic polyps when used by non-expert endoscopists (accredited for standard colonoscopy), but it may improve the clinicians confidence, and increase the specificity for optical diagnosis (Barua et al). Diminutive polyps (1-5 mm) in the rectosigmoid colon can be left in situ when diagnosed with high confidence with a sensitivity of at least 90% and a specificity of at least 80%. To implement the resect-and-discard strategy, a sensitivity of at least 80% is acceptable. This is recommended by the European Society of Gastrointestinal Endoscopy (ESGE) as a strategy to decrease the unnecessary removal of small polyps with a negligible risk of harbouring cancer. Although the resect-and-discard strategy is assessed to be a safe and cost-effective method, it is important to be cautious with lesions in the right colon due to their malignant potential. Reliable CADx systems could enable a more targeted removal of neoplastic polyps, while diminutive non-neoplastic polyps could be left behind. The potential excessive workload due to the CADe system could therefore theoretically be avoided by adding the CADx system. The results so far are promising, suggesting that AI-assisted colonoscopy is superior to conventional colonoscopy when it comes to polyp and adenoma detection. Continued improvement of CADx systems in differentiating the pathology of colorectal lesions is needed, as well as additional clinical studies to assess the potential value of the CADx system. The overall aim of this research is to investigate the quality, and the possible benefits of AI-assistance in colonoscopy. Hopefully this can contribute to a more accurate, safe, and targeted diagnosis and treatment of patients in the future. The investigators have designed a quality assurance study to investigate the effect of real time AI-assisted colonoscopy with the CADx system (GI Genius, Medtronic). This study "REG-093-2022" is a substudy to the RCT "REG-092-2022". The investigators wish to evaluate the diagnostic accuracy of the CADx system.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer, Colorectal Adenoma, Colorectal Neoplasms
Keywords
Artificial intelligence-assisted colonoscopy, Computer-aided polyp characterization, Colorectal adenoma

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
AI-assisted colonoscopy
Arm Type
Other
Arm Description
The patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
Intervention Type
Device
Intervention Name(s)
AI-assisted colonoscopy
Intervention Description
The patients will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
Primary Outcome Measure Information:
Title
True positive findings: Adenomas (histopathologically verified) characterized as adenomas by the AI system
Description
Data from the AI system will be compared with the histopathological data for each removed polyp
Time Frame
5 Months
Title
True negative findings: Non-adenomas (histopathologically verified) characterized as non-adenomas by the AI system
Description
Data from the AI system will be compared with the histopathological data for each removed polyp
Time Frame
5 Months
Title
False positive findings: Non-adenomas (histopathologically verified) characterized as adenomas by the AI system
Description
Data from the AI system will be compared with the histopathological data for each removed polyp
Time Frame
5 Months
Title
False negative findings: Adenomas (histopathologically verified) characterized as non-adenomas by the AI system
Description
Data from the AI system will be compared with the histopathological data for each removed polyp
Time Frame
5 Months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Referred for screening colonoscopy due to a positive faecal immunochemical test (FIT) or for Diagnostic colonoscopy due to symptoms/signs or Post-polypectomy surveillance colonoscopy (only patients who had all detected polyps removed in the previous colonoscopy) Exclusion Criteria: Referral for removal of previous detected polyps Emergency colonoscopy Control colonoscopy due to inflammatory bowel disease (IBD)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ronja Lagström, MD
Phone
+4526800970
Email
rlag@regionsjaelland.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Mustafa Bulut, MD
Email
mub@regionsjaelland.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ronja Lagström, MD
Organizational Affiliation
Zealand University Hospital, Køge
Official's Role
Principal Investigator
Facility Information:
Facility Name
Holbæk Hospital
City
Holbæk
ZIP/Postal Code
4300
Country
Denmark
Individual Site Status
Recruiting
Facility Name
Zealand University Hospital
City
Køge
ZIP/Postal Code
4600
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ronja Lagström, MD
Phone
+4526800970
Email
rlag@regionsjaelland.dk
First Name & Middle Initial & Last Name & Degree
Mustafa Bulut, MD
Email
mub@regionsjaelland.dk
Facility Name
Nykøbing Falster County Hospital
City
Nykøbing Falster
ZIP/Postal Code
4800
Country
Denmark
Individual Site Status
Recruiting
Facility Name
Næstved Hospital
City
Næstved
ZIP/Postal Code
4700
Country
Denmark
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy

We'll reach out to this number within 24 hrs